PexMachina is a quantum applications company focused on computational chemistry and drug discovery, using quantum-native and quantum-inspired simulation methods to help design better cancer treatments. Its work centers on simulating specific compounds and optimizing lead candidates to improve docking, efficacy, and stability while reducing toxicity, with the goal of helping pharmaceutical teams reduce experimental cycles. The company’s public materials name Matthias Kaiser as CEO and co-founder, and also refer to a co-founder CTO and a pharma veteran partner from Johnson & Johnson, though those additional names are not identified in the available sources. The sources do not clearly verify a fundraising round, and they do not consistently establish an HQ city or office locations, so those details are omitted.